Biohub: The Future of Biology is Open-Source with Zuckerberg & Chan

Summary

• Biohub’s $500 million virtual-biology commitment is a patient-capital bet that a major constraint in biology is purpose-built data, not merely larger models. Unlike internet text, much of the necessary biological data does not exist: researchers must invent new imaging, cellular-engineering, and sensing methods to produce it. Zuckerberg argues that this demands “frontier biology and frontier AI,” backed by a 10- to 15-year horizon.
• The operating model deliberately fuses AI and wet labs, building biology hierarchically from proteins to cells to whole systems. Each layer may require qualitatively different data and modeling, but protein interactions underpin cells, which in turn help explain systems such as immunity and inflammation. The setup aims to close an experimental loop in which targeted experiments generate cross-layer data and models support prediction and design.
• The new ESMfold release is the episode’s strongest proof point: a general protein model predicted structures for more than 1.1 billion proteins and supported design capabilities without antibody-specific training. From hundreds of thousands of digital trajectories, the team synthesized 96 proteins in a 96-well plate and found nanomolar binders. “We just designed a model that could understand proteins,” Rives says; protein design emerged from that understanding.
• Open source is Biohub’s distribution strategy and its central nonprofit rationale, not an accessory to the research. Zuckerberg believes wider, faster access will create more impact than monetizing the models, while Chan argues that neutral infrastructure can enlist academia, biotech, and rare-disease communities that commercial prioritization leaves behind. The caveat is explicit: open biological models bring biosafety questions that still need balancing.
• The clinical destination is mechanistic, individualized medicine: connect a person’s genetics to proteins, disease processes, and a bespoke intervention. Chan contrasts that with today’s cohort-based guessing—“Am I represented in this paper?”—and says single-cell atlases could eventually help predict off-target effects such as kidney toxicity before human trials. Her target is to “treat the individual as an individual.”
• Drug design may become dramatically cheaper, but the speakers do not pretend that faster molecules automatically solve clinical development. The hosts frame the incumbent process as roughly 15 years and $1.5 billion, with only about $50 million in molecule and preclinical work versus $1.45 billion in development. Chan’s “less clear” area is how clinical research, delivery, regulation, and safe deployment must change to shorten the distance from bench to patient.
• Biohub’s execution wager is that a stable team of a dozen or a couple dozen exceptional researchers can make meaningful progress without hundreds or thousands, by combining frontier AI, frontier biology, compute, experiments, and new data generation. Five-year success means producing hierarchical world models that are “meaningfully better” and a unique intellectual contribution, after which Zuckerberg expects downstream idea generation to follow. His broader conviction is that AI remains “on track” along an accelerating curve, even when that trajectory feels emotionally unsustainable.

Deep dive

Not yet available upstream; scheduled sync will retry.